F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented oxazolo[4,5-B]pyrazine and oxazolo[4,5-B]pyridine derivatives acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease and cardiovascular disorders.
Chengdu Zeling Biomedical Technology Co. Ltd. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.
Ventus Therapeutics US Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic diseases, autoimmune diseases, and liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
Insilico Medicine Inc. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of obesity, autoimmune disease and inflammatory disorders.
Japan Tobacco Inc. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of arteriosclerosis, gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis [NASH]), Alzheimer’s disease and Parkinson’s disease.
Shenzhen Zhongge Biotechnology Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, liver, cardiovascular, inflammatory, renal, metabolic and neuroinflammatory disorders.
Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.
Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, and inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.
